Levodopa-Carbidopa Composition for Reduced Hydrazine Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease using levodopa are marred by short half-life, pulsatile dopaminergic stimulation, motor fluctuations, dyskinesia, and high extracerebral dopamine concentrations leading to side effects, while existing decarboxylase inhibitors like carbidopa pose safety risks.
Innovation Solution
Formulations combining levodopa with carbidopa and two antioxidants, such as ascorbic acid and cysteine derivatives, to stabilize the mixture and reduce hydrazine toxicity, ensuring continuous dopaminergic stimulation with minimal degradation products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa is administered to treat Parkinson's disease, then dopamine concentration in the brain is restored, but short half-life causes pulsatile dopaminergic stimulation and motor fluctuations
Solution Approach 1:
The patent applies preliminary action by pre-formulating levodopa with decarboxylase inhibitors and antioxidants in a stable composition that enables sustained-release delivery. This preliminary formulation approach allows the drug to maintain therapeutic levels over extended periods without requiring frequent re-dosing, thereby resolving the short half-life issue while maintaining reliable therapeutic efficacy.
2Reliability
If levodopa is administered to restore dopamine concentration, then therapeutic benefit is achieved, but high extracerebral dopamine concentrations cause nausea and side effects
Solution Approach 1:
The patent employs decarboxylase inhibitors as intermediary substances that selectively block peripheral conversion of levodopa to dopamine while allowing central conversion. This intermediary mechanism reduces extracerebral dopamine concentrations and associated side effects like nausea, while maintaining adequate brain dopamine levels for therapeutic efficacy.
Solution Approach 2:
The patent utilizes parameter changes by modifying the chemical environment through antioxidants that prevent oxidative degradation of levodopa and dopamine. This parameter modification (oxidation prevention) stabilizes the drug in the gastrointestinal tract, reducing unpredictable absorption and associated side effects while maintaining therapeutic reliability.
3Quantity of substance
If decarboxylase inhibitors like carbidopa are used to reduce levodopa dose, then peripheral conversion is inhibited, but hydrazine toxicity and safety risks increase
Solution Approach 1:
The patent applies the extraction principle by removing or eliminating the hydrazine component from the decarboxylase inhibitor structure. This is achieved by using non-hydrazine based decarboxylase inhibitors or modified versions that retain therapeutic activity without the toxic hydrazine moiety, thereby reducing levodopa dose requirements while eliminating hydrazine toxicity.
Solution Approach 2:
The patent employs short-acting or rapidly cleared decarboxylase inhibitors that provide transient peripheral blockade without accumulating to toxic levels. This approach allows effective reduction of levodopa dose while minimizing exposure time to potential toxicities, effectively replacing long-acting hydrazine-based inhibitors with safer, shorter-duration alternatives.
4Duration of action of moving object
If sustained-release oral levodopa formulations are used, then continuous delivery is attempted, but efficacy is no better than standard tablets
Solution Approach 1:
The patent utilizes composite materials by formulating levodopa with multiple complementary components including decarboxylase inhibitors, antioxidants, and sustained-release carriers in a single integrated composition. This composite approach synergistically combines prolonged release capability with enhanced stability and bioavailability, achieving continuous delivery that actually improves efficacy compared to standard formulations.
Solution Approach 2:
The patent applies parameter changes by modifying the physical and chemical properties of levodopa through formulation with antioxidants and pH modifiers. These parameter changes (solubility, stability, absorption rate) enable sustained-release formulations to achieve consistent therapeutic levels, thereby improving reliability and efficacy over standard immediate-release tablets.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide stable, continuous dopaminergic therapy with reduced hydrazine levels, minimizing side effects and enhancing treatment efficacy for Parkinson's disease.
Implementation Method 1
Formulations combining levodopa with carbidopa and two antioxidants, such as ascorbic acid and cysteine derivatives, to stabilize the mixture and reduce hydrazine toxicity
Implementation Method 2
Carbidopa is a non-competitive inhibitor of DOPA decarboxylase. When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine.
Data Source
AI summary
Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.